A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Active:	No
Cancer Type:	Leukemia	NCT ID:	NCT05326516
Trial Phases:	Phase I	Protocol IDs:	SNDX-5613-0702 (primary) NCI-2022-04065
Eligibility:	30 Days and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Syndax Pharmaceuticals
NCI Full Details:	http://clinicaltrials.gov/show/NCT05326516

Summary

The purpose of this study is to determine the safety and tolerability of revumenib when
given in combination with 2 different chemotherapy regimens in participants with
relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification,
NPM1c, or NUP98r.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.